SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 17, 2026

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

A post-hoc safety analysis of the phase 3 FLAURA2 trial reports that the onset of grade 3 or higher treatment-related adverse events on first-line osimertinib plus platinum–pemetrexed declined across successive treatment periods, from 43% during four cycles of induction to 14% once patients were receiving osimertinib on its own. The analysis, published in Lung Cancer, divides the combination arm according to each patient's own exposure to the three components of the regimen rather than according to calendar time.
Share

In brief

  • A post-hoc analysis of the FLAURA2 combination arm divided each patient’s treatment into three periods defined by that patient’s own exposure: induction, pemetrexed maintenance, and osimertinib alone.
  • The onset frequency of grade 3 or higher treatment-related adverse events was 43% during induction, 25% during pemetrexed maintenance, and 14% during the osimertinib-only period.
  • Any-grade treatment-related events followed the same direction across the three periods, at 93%, 90% and 58%.
  • Adverse events indicating renal toxicity ran against that pattern, reported in 19% of patients during pemetrexed maintenance against 7% during induction, and all of the maintenance-period events were grade 1 or 2.
  • Adverse events leading to osimertinib discontinuation remained at or below 8% in every period. The analysis covers the combination arm only, and the abstract reports no matching period figures for the osimertinib monotherapy arm.

Study at a glance

  • Cohort: The combination arm of the phase 3 FLAURA2 trial (NCT04035486), analysed post hoc
  • Population: Patients with EGFR-mutated advanced non-small cell lung cancer
  • Treatment: Osimertinib plus platinum–pemetrexed for four cycles, followed by osimertinib plus pemetrexed maintenance, followed by osimertinib alone
  • Periods analysed: Induction (n=276), pemetrexed maintenance (n=201), osimertinib only (n=206)
  • Median duration of each period: 2.8 months, 12.4 months and 17.8 months respectively
  • Treatment-related adverse events, any grade: 93%, 90% and 58% across the three periods
  • Treatment-related adverse events, grade 3 or higher: 43%, 25% and 14%
  • Renal toxicity: 19% during pemetrexed maintenance, all grade 1 or 2, against 7% during induction, which included one grade 3 event
  • What was not reported: Comparable period-by-period figures for the osimertinib monotherapy arm

Grade 3 or higher events fell from 43% in induction to 14% on osimertinib alone

The analysis counts the onset of new adverse events causally related to treatment within each of the three periods. During induction, when patients were receiving osimertinib, platinum and pemetrexed together, 93% had a treatment-related event of any grade and 43% had one of grade 3 or higher. During pemetrexed maintenance the any-grade figure was 90% and the grade 3 or higher figure 25%. During the osimertinib-only period the two figures were 58% and 14%.

Those percentages rest on a re-cut of the combination arm by treatment exposure rather than by randomisation. Induction covered 276 patients, pemetrexed maintenance 201, and the osimertinib-only period 206. The abstract does not account for the difference between those denominators, so the number of patients who left the regimen before reaching a later period, and the reasons they left, are not established by the text reported here.

The measure itself is worth reading carefully. The abstract reports onset frequency, which describes how often fresh toxicity appeared within each period. It is not a measure of how many patients were living with toxicity at any given moment, and the abstract reports no such figure for any of the three periods.

Renal toxicity was the only reported category that rose during pemetrexed maintenance

Adverse events indicating renal toxicity were reported in 19% of patients during pemetrexed maintenance, against 7% during induction. The maintenance events were all grade 1 or 2, and the induction period included one grade 3 event. Pemetrexed is the agent that continues through maintenance after the platinum has stopped, and it is the only one of the toxicity categories named in the abstract that was more frequent later in treatment than at the start.

The abstract reports the frequency and the grades and nothing behind them. There are no creatinine or creatinine-clearance values, no count of dose reductions or interruptions attributed to renal events, and no statement of how many of these events resolved. Whether the higher maintenance figure reflects cumulative pemetrexed exposure or the longer observation window of that period is not addressed in the text reported here.

Maintenance ran a median of 12.4 months and the osimertinib-only period 17.8 months

The three periods are of very different length. Induction ran a median of 2.8 months, with a range of 0.1 to 4.1 months. Pemetrexed maintenance ran a median of 12.4 months, range 0.7 to 56.1. The osimertinib-only period ran a median of 17.8 months, range 0.4 to 56.8. The authors present the length of the two later periods as a finding in its own right, noting that they exceeded 12 and 17 months respectively.

That difference in length matters for reading the percentages above. An onset frequency measured over a median of 2.8 months and one measured over a median of 17.8 months are not observed for the same amount of time per patient, and the abstract reports the figures as period frequencies rather than as exposure-adjusted rates. The decline from 43% to 14% is therefore a comparison between periods of unequal duration, and the longer period is the one with the lower figure.

Discontinuation of osimertinib stayed at or below 8% across the three periods

Adverse events leading to discontinuation of osimertinib were reported at or below 8% in every period. New events indicating haematological, gastrointestinal and skin or nail toxicity were reported most frequently during induction and were mostly grade 1 or 2, with reductions in frequency in the periods that followed.

The design sets the limit on what this can show. The analysis is post hoc, it covers the combination arm alone, and its periods are defined by each patient’s own treatment exposure rather than by random assignment. It describes how the safety profile of the FLAURA2 regimen behaved over time in the patients who received it. It does not measure that profile against the osimertinib monotherapy arm, and the abstract reports no period-by-period comparator figures that would allow a reader to do so. The efficacy claim for the regimen rests on the parent trial, which the authors describe as having significantly improved survival with the addition of platinum–pemetrexed.

Sources

  1. Lung Cancer. Long-term safety of first-line osimertinib plus platinum–pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2 (2026-09-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty David Planchard.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard